A Randomized, Double-blinded, Multicenter, Phase III Clinical Study of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer
Overview
- Phase
- Phase 3
- Intervention
- HLX10
- Conditions
- Gastric Cancer
- Sponsor
- Shanghai Henlius Biotech
- Enrollment
- 642
- Locations
- 15
- Primary Endpoint
- EFS
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
This is a two-arm, randomized, double-blinded, multicenter phase III clinical study to evaluate the efficacy of HLX10 combined with chemotherapy versus placebo combined with chemotherapy for neoadjuvant/adjuvant treatment of gastric cancer.
Subjects will be randomized to the following two arms at 1: 1 ratio:
- Arm A (HLX10 arm): HLX10 combined with chemotherapy will be adopted in the neoadjuvant treatment phase, and HLX10 monotherapy will be administered in the adjuvant treatment phase;
- Arm B (control arm): Placebo combined with chemotherapy will be given in the neoadjuvant treatment phase, and chemotherapy alone will be administered during the adjuvant treatment phase.
Chemotherapy regimen SOX (oxaliplatin + tegafor gimeracil oteracil potassium (S-1)) will be used in the neoadjuvant treatment phase in Arm A and B, and in the adjuvant treatment phase in Arm B.
After randomization, subjects will receive a total of 3 cycles of neoadjuvant treatment with the mentioned treatment regimen.Surgery will be performed within 3-6 weeks after the last cycle of neoadjuvant treatment.All subjects who have completed the surgery will be unblinded after surgery, and adjuvant treatment will be started 3 to 12 weeks after surgery. Subjects randomized to Arm A (HLX10 arm) will continue to receive HLX10 monotherapy for up to 17 cycles (12 months).Subjects in Arm B after surgery (control arm) will continue to use chemotherapy alone (oxaliplatin + S-1) for 5 cycles.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Voluntary participation in the clinical study; fully understands and is informed of the study and has signed the Informed Consent Form (ICF); willing to comply with and able to complete all trial procedures.
- •The gender is not limited. When ICF is signed, the age is ≥ 18 years and ≤ 70 years old.
- •Histologically confirmed untreated gastric cancers, mainly adenocarcinoma.
- •Within 4 weeks prior to first dose, determined by the Independent Radiology Review Committee (IRRC) as: ≥ T3 and number of lymph node metastases ≥ 1 and no distant metastasis.
- •Prior to enrollment, the attending physician will evaluate to determine the eligibility for a R0 resection for the purpose of radical treatment.
- •Have good cardiac function and can be treated with radical resection.
- •tumor specimen testing results are PD-L1 positive (CPS ≥5). Subjects must provide the tumor tissues at screening or in the investigated surgery (if any), for PD-L1 expression level assessment.
- •Within 7 days before the first use of the study drug, ECOG: 0 \~ 1;
- •Expected survival 12 weeks;
- •The functions of the vital organs meet requirements.
Exclusion Criteria
- •Existence of other active malignant tumors within 5 years or at the same time.
- •Plan to perform or have undergone an organ or bone marrow transplant.
- •Myocardial infarction and poorly controlled arrhythmias occurred within 6 months prior to the first dose.
- •Existence of grade III - IV cardiac disorders defined by the NYHA or echocardiogram shows: LVEF (left ventricular ejection fraction) \< 50%.
- •Human immunodeficiency virus (HIV) infection.
- •Patients with active tuberculosis.
- •Patient with previous or current interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-associated pneumonia, severely impaired lung function, etc.
- •Patients who have previously received other antibody/drug treatments for immune checkpoints, such as PD-1, PD-L1, and CTLA4 treatments.
- •Have diseases that may increase the risk of participating in the study and using the study medications, or other severe, acute, and chronic diseases and therefore are judged by the investigator to be unsuitable for clinical studies.
Arms & Interventions
HLX10
HLX10 combined with chemotherapy will be adopted in the neoadjuvant treatment phase, and HLX10 monotherapy will be administered in the adjuvant treatment phase
Intervention: HLX10
Placebo
Placebo combined with chemotherapy will be given in the neoadjuvant treatment phase, and chemotherapy alone will be administered during the adjuvant treatment phase.
Intervention: Placebos
Outcomes
Primary Outcomes
EFS
Time Frame: from randomizationuntil firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 3 years
event-free survival (assessed by independent radiological review committee (IRRC) based on RECIST v1.1)
Secondary Outcomes
- EFS(from randomizationuntil firstly confirmed and recorded disease progression or death (whichever occurs earlier)，assessed up to 3 years)
- DFS(from the start of surgery to disease recurrence or death (for any reason)，assessed up to 3 years)
- 5-year OS rate(OS is the time from randomization to death (of any cause)，assessed up to 5 years)
- pCR rate(after surgery，an average of 6 months)